The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Moderna will soon learn the regulatory fate of its mRNA-based flu shot.
Maddie Meyer/Getty Images
hide caption
toggle caption
Maddie Meyer/Getty Images
Recommendation could pave the way for approval of the mRNA vaccine in adults 50 and up
U.S. health advisers are debating a new kind of flu vaccine. The new shot is made with the same mRNA technology that was key to…
U.S. health advisers are debating a new kind of flu vaccine
Moderna's novel vaccine was at the center of dustup with agency earlier this year
The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more…
WASHINGTON (AP) – A new kind of flu vaccine moved a step closer to the U.S.
